| Target Price consensus revisions : last 18 months |
|
|
|
| Evolution of the average Target Price on ELI LILLY AND COMPANY |
|
|
|
Financial data source
© 2021 S&P Global Market Intelligence
|
|
|
Eli Lilly to buy gene therapy developer Prevail in about $1 bln deal |
| Mean consensus |
OUTPERFORM |
| Number of Analysts |
21 |
| Average target price |
191,87 $ |
| Last Close Price |
206,14 $ |
| Spread / Highest target |
10,1% |
| Spread / Average Target |
-6,92% |
| Spread / Lowest Target |
-41,8% |
Consensus revision (last 18 months)
|
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
